Kemp Dolliver
Stock Analyst at Brookline Capital
(0)
# 3913
Out of 5,270 analysts
24
Total ratings
25.00%
Success rate
-2.73%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Y-mAbs Therapeutics | Initiates Coverage On: Buy | 17 | 5.26 | 223.19% | 1 | Dec 5, 2024 | |
Eyenovia | Downgrades: Hold | n/a | n/a | n/a | 2 | Nov 15, 2024 | |
Verrica Pharmaceutic... | Downgrades: Hold | n/a | n/a | n/a | 2 | Oct 2, 2024 | |
Oncternal Therapeuti... | Downgrades: Hold | n/a | n/a | n/a | 3 | Sep 12, 2024 | |
iBio | Initiates Coverage On: Buy | 4 | 6.15 | -41.46% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 36 | 3.11 | 1057.56% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 32 | 1.44 | 2080.56% | 1 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 27 13 | n/a | n/a | 1 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 100 | 95.46 | 4.76% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 57 | 2.14 | 2563.55% | 2 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 5 | n/a | n/a | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Hold | 25 | 3.77 | 563.13% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 1 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 19 | 14.9 | 25.84% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 8 | 0.98 | 716.33% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 6 | 1.32 | 328.03% | 1 | Feb 2, 2022 |